Metronidazole Polpharma (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced to reactive nitro radical anions. These anions bind to DNA and other critical macromolecules, causing strand breakage and inhibition of nucleic acid synthesis, which ultimately leads to cell death of the targeted bacteria or protozoa.

The dosage of Metronidazole Polpharma is determined by the prescribing clinician based on the infection being treated, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional can set the appropriate dose and treatment duration.

Safety data for Metronidazole in pregnancy are limited, so it should be used only when clearly needed and after risk‑benefit assessment by the prescriber. During breastfeeding, the drug can be excreted in milk; a healthcare professional should evaluate the potential risks before continuing therapy.

To order Metronidazole Polpharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic organisms and certain protozoa, offering a broad spectrum against these pathogens. Compared with beta‑lactam antibiotics, it provides a different mechanism of action and is often preferred when resistance to other classes is a concern or when treating protozoal infections.

Metronidazole Polpharma should be stored below 25 °C, in its original packaging, protected from light and moisture. Maintaining these conditions helps preserve the stability and potency of the intravenous solution throughout its shelf life.

Metronidazole Polpharma is supplied as an intravenous solution and is administered by a qualified healthcare professional through a vein. The infusion rate and duration are determined by the prescribing clinician based on the indication and patient-specific factors.

Serious risks include severe allergic reactions (such as anaphylaxis), peripheral neuropathy, seizures, and hepatotoxicity. Patients should be monitored for signs of these reactions, and therapy should be discontinued immediately if any serious adverse event occurs.

Metronidazole Polpharma should be avoided in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for patients with severe hepatic impairment, a history of seizures, or those taking medications that may interact dangerously, such as disulfiram.